HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!

2022-10-28

---

AstraZeneca (AstraZeneca) recently reported positive, high-level results from its phase II trial of SERENA 2. This is a randomized, open label, parallel group, multicenter phase 2 trials, is a large-scale clinical part of the project, the project focused on camizestrant, this is a kind of powerful next-generation purely oral JiangXieJi selective estrogen receptor and estrogen receptor alpha blockers and are being developed as a single-agent therapy or combined with other drugs, To address an unmet medical need in the field of hormone receptor-positive breast cancer